Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 7, pp 981–982 | Cite as

Updated analysis on polypharmacy and mortality from the ESTHER study

  • Ben Schöttker
  • Dana Clarissa Muhlack
  • Liesa Katharina Hoppe
  • Bernd Holleczek
  • Hermann Brenner
Letter to the Editor
  • 112 Downloads

Dear Editor,

In the August 2017 issue, our group published the article “Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication” [1]. The most important limitation of the analyses in this article was the low number of 87 events of non-cancer mortality during a mean follow-up time of 4.4 years from the German, population-based ESTHER cohort. We now extended the mortality follow-up and would like to present the updated results. We again used the study sample of 2,687 men and women with medication data collected via the “brown-bag method” 2008–2010 [2], who were on average 70 years old.

Until end of 2015 (mean follow-up of 5.7 years), 138 study participants died of a cause other than cancer. We repeated the statistical analyses with the same methodology as described previously [ 1]. Table 1shows the updated results of Cox proportional hazards regression...

Notes

Funding information

This study was funded by the Federal Ministry of Education and Research (Berlin, Germany) [Grant number 01GY1320A].

Compliance with ethical standards

The ESTHER study was approved by the ethics committees of the Medical Faculty of the University of Heidelberg and the Medical Association of Saarland and is being conducted in accordance with the declaration of Helsinki.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Schöttker B, Saum KU, Muhlack DC, Hoppe LK, Holleczek B, Brenner H (2017) Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol 73:1041–1048CrossRefPubMedGoogle Scholar
  2. 2.
    Nathan A, Goodyer L, Lovejoy A, Rashid A (1999) ‘Brown bag’ medication reviews as a means of optimizing patients’ use of medication and of identifying potential clinical problems. Fam Pract 16:278–282CrossRefPubMedGoogle Scholar
  3. 3.
    Hudon C, Fortin M, Vanasse A (2005) Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. J Clin Epidemiol 58:603–608CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Clinical Epidemiology and Aging ResearchGerman Cancer Research CenterHeidelbergGermany
  2. 2.Network Aging ResearchUniversity of HeidelbergHeidelbergGermany
  3. 3.Institute of Health Care and Social SciencesFOM UniversityEssenGermany
  4. 4.Saarland Cancer RegistrySaarbrückenGermany

Personalised recommendations